TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
ConditionBladder Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Eligibility criteria
Qualifiers
Age ≥ 18 years;
Signed ICF, including consent for FFPE tumor tissue sample testing;
Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
T1 tumor
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov